BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to
the treatment and supportive care of cancer and AIDS patients, today announced a turnover of of €7.5
million for 2009.
Loramyc® sales in France totaled €2.1 million – double 2008′s figure and in line with the company’s
stated objectives. These recurring revenues confirm the success of Loramyc®, which is increasingly
being chosen by hospital-based specialists as the standard of care for oropharyngeal candidiasis. As
of December 31, 2009, over 50,000 patients had received Loramyc®.
Co-promotion of Seroplex® (initiated in mid-2009) generated €0.3 million in turnover. This fixed-term
agreement (which expired on December 31, 2009) proved the value and the efficacy of BioAlliance
Pharma’s sales force. The company has just signed a new agreement with Eisai SAS France for the
co-promotion of the product Aequasyal®, indicated in the treatment of dry mouth (hyposialia). This
disabling disease is very frequent in cancer patients and needs supportive care treatment.
Income from collaborations and licensing agreements totaled €5.1 million for 2009, compared with €7
million in 2008. This variation is due to the staggered payment of non-recurring revenues.
As of December 31, 2009, BioAlliance Pharma’s cash reserves amounted to €14.7 million. The cash
burn is in line with the company’s business plan. BioAlliance Pharma expects to receive a $20 million
payment from Par Pharmaceutical/Strativa in the first half of 2010 when Loramyc® is granted
marketing authorization in the United States. BioAlliance Pharma also expects early repayment of its
2009 research tax credit (estimated at around €2 million).
“In 2009, BioAlliance Pharma reaffirmed its positioning in supportive care with hospital-based
oncologists”, stated Dominique Costantini MD, BioAlliance Pharma’s President and CEO. “The
commercial success of Loramyc® in France will be very useful for our international partners – notably
Par Pharmaceutical/Strativa, which is set to launch Loramyc® in the United States in the second half of
2010. We are confident in our ability to grow our recurring revenues in 2010 still further, with the arrival
of a second product (Setofilm®) and the initiation of a strategic alliance within Europe”.